Abstract
Development and validation of novel diagnostic and prognostic tools for cancer patients are a clinically unmet need, especially to help predicting survival or treatment response and toxicity. Metabolomics provides a dynamic portrait of the metabolic state of a tumour in response to pathophysiological stimuli (such as tumour growth or tumour shrinkage) and helps us understand the molecular mechanism sustaining these phenomena. Recent literature presented encouraging data on potential applications of metabolomics in translational research. Analysis of alterations of the metabolic network may lead to identify novel biomarkers and/or therapeutic target.
Résumé
La prise en charge des patients atteints de cancer nécessite le développement et la validation de nouveaux outils diagnostiques, pronostiques et/ou prédictifs de la réponse ou de la toxicité des traitements. La métabolomique dresse un portrait dynamique de l’état métabolique d’une tumeur, en réponse à des stimuli physiopathologiques (prolifération ou fonte tumorale), permettant la compréhension des mécanismes moléculaires impliqués. Les premières études publiées présentent des données encourageantes pour la poursuite de l’utilisation de lamétabolomique dans la recherche de transfert en cancérologie. L’étude des perturbations du réseau métabolique pourrait permettre en effet d’identifier de nouveaux biomarqueurs et/ou de nouvelles cibles thérapeutiques.
Similar content being viewed by others
Références
Bathen TF, Jensen LR, Sitter B, et al. (2007) MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 104: 181–189
Benyoseph O, Badargoffer RS, Morris PG, et al. (1993) Glycerol 3-phosphate and lactate as indicators of the cerebral cytoplasmic redox state in severe and mild hypxia respectively: a C-13-NMR and P-31-NMR study. Biochem J 291: 915–919
Cairns RA, Papandreou I, Sutphin PD, et al. (2007) Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 104: 9445–9450
Chan EC, Koh PK, Mal M, et al. (2009) Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 8: 352–3561
Cheng LL, Chang IW, Louis DN, et al. (1998) Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 58: 1825–1832
Cheng LL, Ma MJ, Becerra L, et al. (1997) Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 94: 6408–6413
Clayton TA, Lindon JC, Cloarec O, et al. (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073–1077
Coy JF, Dressler D, Wilde J, et al. (2005) Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 51: 257–273
Cui Q, Lewis IA, Hegeman AD, et al. (2008) Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotechnol 26: 162–164
Dettmer K, Aronov PA, Hammock BD (2007) Mass spectrometry-based metabolomics. Mass Spectrom Rev 26: 51–78
Dunn WB, Ellis DI (2005) Metabolomics: current analytical platforms and methodologies. TrAC, Trends Anal Chem 24: 285–294
Eisen MB, Spellman PT, Brown PO, et al. (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863–4868
El-Deredy W, Ashmore SM, Branston NM, et al. (1997) Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks. Cancer Res 57: 4196–4199
Ernst RR, Bodenhausen G, Wokaun A (1987) Principles of nuclear magnetic resonance in one and two dimensions. Clarendon Press, Oxford
Fiehn O, Kopka J, Dormann P, et al. (2000) Metabolite profiling for plant functional genomics. Nat Biotechnol 18: 1157–1161
Glunde K, Serkova NJ (2006) Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7: 1109–1123
Griffin JL, Shockcor JP (2004) Metabolic profiles of cancer cells. Nat Rev Cancer 4: 551–561
Holmes E, Loo RL, Stamler J, et al. (2008) Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453: 396–400
Howe FA, Barton SJ, Cudlip SA, et al. (2003) Metabolic profiles of human brain tumors using quantitative in vivo H-1 magnetic resonance spectroscopy. Magn Reson Med 49: 223–232
Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13: 472–482
Lindon JC, Holmes E, Nicholson JK (2003) So whats the deal with metabonomics? Metabonomics measures the fingerprint of biochemical perturbations caused by disease, drugs, and toxins. Anal Chem 75: 384A–391A
Lyng H, Sitter B, Bathen TF, et al. (2007) Metabolic mapping by use of high-resolution magic angle spinning H-1 MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer 7: 11
Madsen R, Lundstedt T, Trygg J (2010) Chemometrics in metabolomics: a review in human disease diagnosis. Anal Chim Acta 659: 23–33
Nicholson JK, Lindon JC (2008) Systems biology-metabonomics. Nature 455: 1054–1056
Odunsi K, Wollman RM, Ambrosone CB, et al. (2005) Detection of epithelial ovarian cancer using H-1-NMR-based metabonomics. Int J Cancer 113: 782–788
Piotto M, Moussallieh FM, Dillmann B, et al. (2009) Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning H-1 magnetic resonance spectroscopy. Metabolomics 5: 292–301
Powers R (2009) NMR metabolomics and drug discovery. Magn Reson Chem 47: S2–S11
Preul MC, Caramanos Z, Collins DL, et al. (1996) Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 2: 323–325
Robertson DG (2005) Metabonomics in toxicology: a review. Toxicol Sci 85: 809–822
Shulaev V (2006) Metabolomics technology and bioinformatics. Brief Bioinform 7: 128–139
Spratlin JL, Serkova NJ, Eckhardt SG (2009) Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 15: 431–440
Sreekumar A, Poisson LM, Rajendiran TM, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910–914
Stahle L, Wold S (1989) Analysis of variance (Anova). Chemometrics Intellig Lab Syst 6: 259–272
Swanson MG, Zektzer AS, Tabatabai ZL, et al. (2006) Quantitative analysis of prostate metabolites using H-1 HR-MAS spectroscopy. Magn Reson Med 55: 1257–1264
Tamayo P, Slonim D, Mesirov J, et al. (1999) Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 96: 2907–2912
Trygg J, Wold S (2002) Orthogonal projections to latent structures (O-PLS). J Chemometrics 16: 119–128
Ulrich EL, Akutsu H, Doreleijers JF, et al. (2008) BioMagResBank. Nucleic Acids Res 36: D402–D408
Warburg O (1956) Origin of cancer cells. Science 123: 309–314
Wishart DS (2007) Current progress in computational metabolomics. Brief Bioinform 8: 279–293
Wishart DS, Knox C, Guo AC, et al. (2009) HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37: D603–D610
Wold S, Esbensen K, Geladi P (1987) Principal component analysis. Chemometrics Intellig Lab Syst 2: 37–52
Wold S, Sjostrom M, Eriksson L (2001) PLS-regression: a basic tool of chemometrics. Chemometrics Intellig Lab Syst 58: 109–130
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Jobard, E., Trédan, O., Elena, B. et al. La métabolomique: un nouvel outil pour la recherche translationnelle en cancérologie. Oncologie 12, 409–415 (2010). https://doi.org/10.1007/s10269-010-1913-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-010-1913-8